| Dr Sean D Cunningham, MD | |
|
1215 Pleasant St, Ste 206, Des Moines, IA 50309 | |
| (515) 875-9092 | |
| (515) 875-9828 |
| Full Name | Dr Sean D Cunningham |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 48 Years |
| Location | 1215 Pleasant St, Des Moines, Iowa |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023001559 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | MD-20853 (Iowa) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Unitypoint At Home | Urbandale, IA | Home health agency |
| Wesley Life Home Health | Johnston, IA | Home health agency |
| Unitypoint Health - Des Moines Iowa Methodist Medi | Des moines, IA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Iowa Clinic Pc | 4082513742 | 273 |
News Archive
Gen-Probe's PROGENSA® PCA3 assay can help determine whether men suspected of having prostate cancer should undergo a repeat biopsy, according to data from the two largest studies to date of the molecular urine test. The studies were presented last week at the American Society of Clinical Oncology's (ASCO) Genitourinary (GU) Cancers Symposium in San Francisco.
During the final presidential debate, President Donald Trump claimed that 180 million people would lose their private health insurance to socialized medicine if the Democratic presidential nominee, former Vice President Joe Biden, is elected president.
They're the prime demographic for developing eating disorders, yet new research out of the University of Cincinnati suggests that it could be difficult for college students to notice the warning signs. On Oct. 31, Ashlee Hoffman, a UC doctoral student in health promotion and education, will present her research, titled, "University Students' Knowledge of An Ability to Identify Disordered Eating, Warning Signs and Risk Factors," at the American Public Health Association's 139th annual meeting and exposition in Washington, DC.
Alnylam Biotherapeutics, a division of Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the presentation of new data at the Cell Culture Engineering XII conference held in Alberta, Canada from April 25 - 30, 2010. Alnylam Biotherapeutics was formed by Alnylam to develop RNAi technologies for application in manufacturing processes for biotherapeutic products, including recombinant proteins and monoclonal antibodies.
› Verified 2 days ago
| Entity Name | The Iowa Clinic Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346233178 PECOS PAC ID: 4082513742 Enrollment ID: O20040102000222 |
News Archive
Gen-Probe's PROGENSA® PCA3 assay can help determine whether men suspected of having prostate cancer should undergo a repeat biopsy, according to data from the two largest studies to date of the molecular urine test. The studies were presented last week at the American Society of Clinical Oncology's (ASCO) Genitourinary (GU) Cancers Symposium in San Francisco.
During the final presidential debate, President Donald Trump claimed that 180 million people would lose their private health insurance to socialized medicine if the Democratic presidential nominee, former Vice President Joe Biden, is elected president.
They're the prime demographic for developing eating disorders, yet new research out of the University of Cincinnati suggests that it could be difficult for college students to notice the warning signs. On Oct. 31, Ashlee Hoffman, a UC doctoral student in health promotion and education, will present her research, titled, "University Students' Knowledge of An Ability to Identify Disordered Eating, Warning Signs and Risk Factors," at the American Public Health Association's 139th annual meeting and exposition in Washington, DC.
Alnylam Biotherapeutics, a division of Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the presentation of new data at the Cell Culture Engineering XII conference held in Alberta, Canada from April 25 - 30, 2010. Alnylam Biotherapeutics was formed by Alnylam to develop RNAi technologies for application in manufacturing processes for biotherapeutic products, including recombinant proteins and monoclonal antibodies.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Sean D Cunningham, MD Po Box 424, Des Moines, IA 50302-0424 Ph: (515) 875-9925 | Dr Sean D Cunningham, MD 1215 Pleasant St, Ste 206, Des Moines, IA 50309 Ph: (515) 875-9092 |
News Archive
Gen-Probe's PROGENSA® PCA3 assay can help determine whether men suspected of having prostate cancer should undergo a repeat biopsy, according to data from the two largest studies to date of the molecular urine test. The studies were presented last week at the American Society of Clinical Oncology's (ASCO) Genitourinary (GU) Cancers Symposium in San Francisco.
During the final presidential debate, President Donald Trump claimed that 180 million people would lose their private health insurance to socialized medicine if the Democratic presidential nominee, former Vice President Joe Biden, is elected president.
They're the prime demographic for developing eating disorders, yet new research out of the University of Cincinnati suggests that it could be difficult for college students to notice the warning signs. On Oct. 31, Ashlee Hoffman, a UC doctoral student in health promotion and education, will present her research, titled, "University Students' Knowledge of An Ability to Identify Disordered Eating, Warning Signs and Risk Factors," at the American Public Health Association's 139th annual meeting and exposition in Washington, DC.
Alnylam Biotherapeutics, a division of Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the presentation of new data at the Cell Culture Engineering XII conference held in Alberta, Canada from April 25 - 30, 2010. Alnylam Biotherapeutics was formed by Alnylam to develop RNAi technologies for application in manufacturing processes for biotherapeutic products, including recombinant proteins and monoclonal antibodies.
› Verified 2 days ago
Dr. Joshua C Lukenbill, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1221 Pleasant Street, Suite 100, Des Moines, IA 50309 Phone: 515-282-2921 Fax: 515-282-1035 | |
Dr. Akshay Mahesh Khatri, M.B.B.S., MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1221 Pleasant St Ste 300, Des Moines, IA 50309 Phone: 515-241-4200 Fax: 515-241-4048 | |
Ravinder Dervesh, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 411 Laurel St Ste 1225, Des Moines, IA 50314 Phone: 515-633-3770 Fax: 515-288-6713 | |
Mr. David Augusto Terrero Salcedo, M.D Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1221 Pleasant St Ste 300, Des Moines, IA 50309 Phone: 515-241-4200 Fax: 515-241-4048 | |
Tyler Mumm, DO Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1111 6th Ave, Des Moines, IA 50314 Phone: 515-643-2261 Fax: 515-643-5802 | |
Bilal Hasan Baig, DO Internal Medicine Medicare: Medicare Enrolled Practice Location: 1200 Pleasant St, Des Moines, IA 50309 Phone: 515-241-6636 Fax: 515-241-4080 |